Ocular Therapeutix Q1 2024 Adj EPS $(0.28) Misses $(0.19) Estimate, Sales $14.774M Miss $15.414M Estimate
Ocular Therapeutix Q1 2024 Adj EPS $(0.28) Misses $(0.19) Estimate, Sales $14.774M Miss $15.414M Estimate
Ocular Therapeutix 2024年第一季度調整後每股收益美元 (0.28) 未達到預期 (0.19) 美元，銷售額爲147.74億美元，未達到1541.4萬美元的預期
Ocular Therapeutix (NASDAQ:OCUL) reported quarterly losses of $(0.28) per share which missed the analyst consensus estimate of $(0.19) by 47.37 percent. The company reported quarterly sales of $14.774 million which missed the analyst consensus estimate of $15.414 million by 4.15 percent. This is a 10.47 percent increase over sales of $13.374 million the same period last year.
Ocular Therapeutix（納斯達克股票代碼：OCUL）公佈的季度虧損爲每股0.28美元（0.28美元），低於分析師普遍預期的47.37美元（0.19美元）。該公司公佈的季度銷售額爲147.74億美元，比分析師普遍預期的1541.4萬美元低4.15％。這比去年同期的133.74萬美元的銷售額增長了10.47％。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。